DK0589840T3 - Omdannede monoklonale antistoffer mod en immunoglobulinisotype - Google Patents
Omdannede monoklonale antistoffer mod en immunoglobulinisotypeInfo
- Publication number
- DK0589840T3 DK0589840T3 DK93810653T DK93810653T DK0589840T3 DK 0589840 T3 DK0589840 T3 DK 0589840T3 DK 93810653 T DK93810653 T DK 93810653T DK 93810653 T DK93810653 T DK 93810653T DK 0589840 T3 DK0589840 T3 DK 0589840T3
- Authority
- DK
- Denmark
- Prior art keywords
- monoclonal antibodies
- converted
- immunoglobulin isotype
- immunoglobulin
- isotype
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929220228A GB9220228D0 (en) | 1992-09-24 | 1992-09-24 | Reshaped monoclonal antibodies against an immunologlobulin isotype |
| US95280292A | 1992-09-25 | 1992-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0589840T3 true DK0589840T3 (da) | 2004-07-26 |
Family
ID=26301683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK93810653T DK0589840T3 (da) | 1992-09-24 | 1993-09-15 | Omdannede monoklonale antistoffer mod en immunoglobulinisotype |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP0589840B1 (es) |
| JP (2) | JP3636737B2 (es) |
| KR (1) | KR100298608B1 (es) |
| CN (2) | CN1078250C (es) |
| AT (1) | ATE264388T1 (es) |
| AU (1) | AU675449B2 (es) |
| CA (1) | CA2106719C (es) |
| CY (1) | CY2583B2 (es) |
| DE (1) | DE69333484T2 (es) |
| DK (1) | DK0589840T3 (es) |
| ES (1) | ES2219640T3 (es) |
| FI (2) | FI114550B (es) |
| HK (1) | HK1056182A1 (es) |
| IL (2) | IL107049A (es) |
| MX (1) | MX9305920A (es) |
| NO (1) | NO318210B1 (es) |
| NZ (1) | NZ248743A (es) |
| PT (1) | PT589840E (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA966075B (en) * | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| AU7156996A (en) * | 1995-09-13 | 1997-04-01 | Genentech Inc. | Methods for treatment of interstitial cystitis |
| US6127524A (en) * | 1996-10-18 | 2000-10-03 | Dade Behring Inc. | Binding molecules and computer-based methods of increasing the binding affinity thereof |
| AU2103699A (en) * | 1998-01-29 | 1999-08-16 | Tse Wen Chang | Treating atopic dermatitis with ige antagonists |
| US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| EP2267032A3 (en) * | 2002-11-08 | 2011-11-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
| WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
| ES2575547T3 (es) * | 2003-02-01 | 2016-06-29 | Tanox, Inc. | Anticuerpos anti-IgE de humano de alta afinidad |
| SG183683A1 (en) * | 2004-02-02 | 2012-09-27 | Tanox Inc | Identification of novel ige epitopes |
| CN102271707B (zh) | 2008-10-29 | 2015-04-08 | 阿布林克斯公司 | 单域抗原结合性分子的制剂 |
| WO2010056550A1 (en) | 2008-10-29 | 2010-05-20 | Wyeth Llc | Methods for purification of single domain antigen binding molecules |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2724625B2 (ja) * | 1987-12-31 | 1998-03-09 | タノックス・バイオシステムズ・インコーポレーテッド | ＩｇＥ産出性Ｂリンパ球上の独特な抗原決定基 |
| US5104604A (en) * | 1989-10-05 | 1992-04-14 | Dexter Electronic Materials Div. Of Dexter Corp. | Flame retardant epoxy molding compound, method and encapsulated device method of encapsulating a semiconductor device with a flame retardant epoxy molding compound |
| JP2988635B2 (ja) * | 1990-09-18 | 1999-12-13 | 塩野義製薬株式会社 | ヒトＩｇＥに対するモノクローナル抗体 |
| WO1992017207A1 (en) * | 1991-03-26 | 1992-10-15 | Tanox Biosystems, Inc. | MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS |
| CA2113813C (en) * | 1991-08-14 | 2005-04-12 | Paula M. Jardieu | Immunoglobulin variants for specific fc epsilon receptors |
-
1993
- 1993-09-15 DK DK93810653T patent/DK0589840T3/da active
- 1993-09-15 AT AT93810653T patent/ATE264388T1/de not_active IP Right Cessation
- 1993-09-15 DE DE69333484T patent/DE69333484T2/de not_active Expired - Lifetime
- 1993-09-15 EP EP93810653A patent/EP0589840B1/en not_active Expired - Lifetime
- 1993-09-15 EP EP04008222A patent/EP1452542A3/en not_active Withdrawn
- 1993-09-15 ES ES93810653T patent/ES2219640T3/es not_active Expired - Lifetime
- 1993-09-15 PT PT93810653T patent/PT589840E/pt unknown
- 1993-09-20 IL IL107049A patent/IL107049A/en not_active IP Right Cessation
- 1993-09-20 IL IL173988A patent/IL173988A0/en unknown
- 1993-09-20 AU AU47488/93A patent/AU675449B2/en not_active Ceased
- 1993-09-22 FI FI934145A patent/FI114550B/fi active IP Right Grant
- 1993-09-22 CA CA002106719A patent/CA2106719C/en not_active Expired - Fee Related
- 1993-09-22 NZ NZ248743A patent/NZ248743A/en not_active IP Right Cessation
- 1993-09-23 NO NO19933394A patent/NO318210B1/no not_active IP Right Cessation
- 1993-09-24 KR KR1019930019631A patent/KR100298608B1/ko not_active IP Right Cessation
- 1993-09-24 CN CN93119845A patent/CN1078250C/zh not_active Expired - Fee Related
- 1993-09-24 JP JP23818093A patent/JP3636737B2/ja not_active Expired - Fee Related
- 1993-09-24 MX MX9305920A patent/MX9305920A/es not_active IP Right Cessation
-
2001
- 2001-12-14 CN CNB011436433A patent/CN1254487C/zh not_active Expired - Fee Related
-
2003
- 2003-11-21 HK HK03108492A patent/HK1056182A1/xx not_active IP Right Cessation
-
2004
- 2004-05-19 FI FI20040696A patent/FI115838B/fi active IP Right Grant
- 2004-07-07 JP JP2004201096A patent/JP3718214B2/ja not_active Expired - Fee Related
-
2005
- 2005-09-08 CY CY0500048A patent/CY2583B2/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2583B2 (en) | Reshaped monoclonal antibodies against an immunoglobulin isotype | |
| ATE512224T1 (de) | Rekonstituierter menschlicher anti-hm.1 antikörper | |
| DK0758904T3 (da) | Fremgangsmåder og sammensætninger til behandling af glomerulonephritis | |
| NO2017040I1 (no) | Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC | |
| DK1212422T3 (da) | Humane CTLA-4-antistoffer og anvendelserne deraf | |
| DK0986577T3 (da) | Opsonisk og beskyttende monoklonale og kimære antistoffer specifikke for lipoteichoicsyre af grampositive bakterier | |
| DE59209129D1 (de) | Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression | |
| ATE166230T1 (de) | Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock | |
| ES2116298T3 (es) | Nuevo metodo de tratamiento de la depresion. | |
| DE69125485T2 (de) | Verfahren und zwischenprodukte synthetischer antikörperderivate | |
| ATE199321T1 (de) | Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen. | |
| MX9301858A (es) | Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv. | |
| DE69029858T2 (de) | Behandlung von einer autoimmun-krankheit | |
| RU93035807A (ru) | Способ лечения юношеского эпифизиолиса |